The DOI matches its Crossref record.
Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde
Abstract
Quinolones are a very important family of antibacterial agents that are widely prescribed for the treatment of infections in humans. Although the founding members of this drug class had little clinical impact, successive generations include the most active and broad spectrum oral antibacterials currently in use. In contrast to most other anti-infective drugs, quinolones do not kill bacteria by inhibiting a critical cellular process. Rather, they corrupt the activities of two essential enzymes, DNA gyrase and topoisomerase IV, and induce them to kill cells by generating high levels of double-stranded DNA breaks. A second unique aspect of quinolones is their differential ability to target these two enzymes in different bacteria. Depending upon the bacterial species and quinolone employed, either DNA gyrase or topoisomerase IV serves as the primary cytotoxic target of drug action. While this unusual feature initially stymied development of quinolones with high activity against Gram-positive bacteria, it ultimately opened new vistas for the clinical use of this drug class. In addition to the antibacterial quinolones, specific members of this drug family display high activity against eukaryotic type II topoisomerases, as well as cultured mammalian cells and in vivo tumor models. These antineoplastic quinolones represent a potentially important source of new anticancer agents and provide an opportunity to examine drug mechanism across divergent species. Because of the clinical importance of quinolones, this review will discuss the mechanistic basis for drug efficacy and interactions between these compounds and their topoisomerase targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Self-citationPham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
Collin, F., Karkare, S., & Maxwell, A. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3557-z · Cited by 606
Antibacterial Nanomaterials: Mechanisms, Impacts on Antimicrobial Resistance and Design Principles
Xie, M., Gao, M., Yun, Y., Malmsten, M., Rotello, V. M., Zboril, R., Akhavan, O., Kraskouski, A., Amalraj, J., Cai, X., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202217345 · Cited by 491
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462
Self-citation
Metadata
- Authors
- Anderson, V., & Osheroff, N.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2001-03-01
- Volume
- 7
- Issue
- 5
- Pages
- 337-353
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2079924617
- Cited by
- 190
- References
- 0
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde. https://app.cochat.ai/papers/10.2174/1381612013398013
- The paper
- Anderson, V., & Osheroff, N. (2001). Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde. Current Pharmaceutical Design. https://doi.org/10.2174/1381612013398013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.